Global Guillain-Barré Syndrome Treatment Market 2019-2023 - Recent Approvals of Novel Immunoglobulins from Regulatory Bodies Are Expected to Propel Growth - ResearchAndMarkets.com

December 6, 2018

DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Guillain-Barré Syndrome Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The Guillain-Barré syndrome treatment market is projected to register a CAGR of more than 5% by 2023.

The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barré syndrome.

Immunoglobulins are the first line treatment of Guillain-Barré syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barré syndrome treatment market during the forecast period.

Currently there is no cure for Guillain-Barré syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barré syndrome.

Key Players

CSL Grifols Octapharma Shire Kedrion

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by Product

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/5d6fw5/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005678/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/06/2018 11:44 AM/DISC: 12/06/2018 11:44 AM


Update hourly